Please assess the completion status of the following clinical trial:

Trial Title: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment~* Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.~* Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.~Exclusion Criteria:~* History of seizures or of a condition with risk of seizures.~* Subjects with schizophrenia that have not responded at all to current treatment.~* Pregnant or nursing females, and females of child bearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PF-02545920 (5mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-02545920 (15mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).